Inflammation and lung carcinogenesis: applying findings in prevention and treatment-Reference-Cited by-同舟云学术

Inflammation and lung carcinogenesis: applying findings in prevention and treatment

Published:2007-10 Issue:10 Volume:7 Page:1405-1421
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Peebles Katherine A,Lee Jay M,Mao Jenny T,Hazra Saswati,Reckamp Karen L,Krysan Kostyantyn,Dohadwala Mariam,Heinrich Eileen L,Walser Tonya C,Cui Xiaoyan,Baratelli Felicita E,Garon Edward,Sharma Sherven,Dubinett Steven M

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.7.10.1405

Reference225 articles.

1. Cancer Statistics, 2007

2. Inflammation and cancer

3. Paradoxical roles of the immune system during cancer development

4. Perspectives on Pulmonary Inflammation and Lung Cancer Risk in Cigarette Smokers

5. State of the Art. Chronic Obstructive Pulmonary Disease, Inflammation, and Lung Cancer

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the causality between chronic obstructive pulmonary disease and its common comorbidities using bidirectional Mendelian randomization;European Journal of Medical Research;2024-02-26

2. Live or Heat-Killed Lactobacillus rhamnosus Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model;International Journal of Molecular Sciences;2022-10-22

3. The Association Between Cyclooxygenase-2 –1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study;Frontiers in Genetics;2022-04-05

4. Elevated air quality index and fine particulate matter levels contribute to the poor prognosis and progression of nonsmall‐cell lung cancer: A cohort study combined with external validation;Cancer Medicine;2022-03-21

5. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC;Pharmacological Research;2021-08